The Children's Oncology Group Routinely Applies “Lack of Efficacy” Interim Monitoring to Its Randomized Clinical Trials

ISSN： 1536-0075

Source： American Journal of Bioethics, Vol.11, Iss.3, 2011-03, pp. : 18-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report

By Korn Edward Freidlin Boris

American Journal of Bioethics, Vol. 11, Iss. 3, 2011-03 ,pp. : 2-10

Routledge Ltd

Access to resources Recommend Favorite

The Molecular Basis of the Kidd Blood Group Polymorphism and Its Lack of Association With Type 1 Diabetes Susceptibility

By Olivès Bernadette

Human Molecular Genetics, Vol. 6, Iss. 7, 1997-01 ,pp. : 1017-1020

Oxford University Press

Access to resources Recommend Favorite

Precautionary Harm Disclosure in Clinical Trials

By Wu Kevin Chien-Chang

American Journal of Bioethics, Vol. 9, Iss. 8, 2009-08 ,pp. : 43-45

Routledge Ltd

Access to resources Recommend Favorite

Sham Surgery in Randomized Trials: Additional Requirements Should Be Satisfied

By Mann Howard

American Journal of Bioethics, Vol. 3, Iss. 4, 2003-0 ,pp. : 5-7

Routledge Ltd

Access to resources Recommend Favorite

Can Contracts Enhance Participant Autonomy in Clinical Trials?

By Buccafurni Diana

American Journal of Bioethics, Vol. 11, Iss. 4, 2011-04 ,pp. : 24-25

Routledge Ltd

Access to resources Recommend Favorite